The CRISPR market size is projected to grow from USD 2.87 billion in 2025 to USD 12.22 billion by 2035, representing a CAGR of 15.60% during the forecast period till 2035. In September 2024, Pairwise secured USD 40 million in Series C funding to advance gene editing in plant breeding. This funding was led by Deerfield Management and other returning investors along with new investor Corteva. Overall, the future of CRISPR is promising however, regulatory uncertainties and complexity in off-target...

The global stem cell therapy market for cardiovascular and metabolic disorders is likely to grow to $3.3 billion by 2030, driven by the rising incidence of these disorders. Cardiovascular disorders and metabolic disorders are considered to be amongst the leading causes of death worldwide. According to a study conducted by RTI International for the American Heart Association, the prevalence of cardiovascular diseases is expected to rise to 45% of the overall US population, while affiliated costs...

Lupus is a serious, potentially fatal, autoimmune disease that attacks healthy tissue. It is worth metioning that Benlysta

After years of research tracing back to the 18th century, a gamut of novel therapies namely, CAR-T, TCR and TIL therapies, have finally reached a point of maturity. Notably, a high therapeutic potential and favorable clinical outcomes outweigh the challenges such as high cost, tedious manufacturing and ethical concerns serving as the roadblocks to the progress of the therapy. With no marketed products, this emerging field is still in its infancy. Research institutions, through investment of time...

The PARP inhibitors market is estimated to be worth $8 billion in 2030 and is expected to grow at CAGR of 18% during the forecast period. Cancer is known to be one of the leading causes of death worldwide. According to the International Agency for Research on Cancer (IARC), close to 17 million new cancer cases were reported in 2018, worldwide. By 2040, it is estimated that the aforementioned number is likely to grow to 27.5 million. Therefore, there is a pressing need for more specific and poten...

Bispecific antibodies (bsAbs) are artificial antibodies created by joining together two monoclonal antibodies (or parts) that target different epitopes.The resulting antibody has binding affinities for 2 or 3 different epitopes concurrently. Various technology platforms have been used for bsAbs production over the years. These platforms are based on the concepts of chemical crosslinking, hybrid hybridomas, with the latest being recombinant techniques. As of now, only 2 bsAbs, Removab and Blincyt...

The global biotherapeutics market is expected to grow from $4.4 billion to $11.0 billion by 2025 at a CAGR of 9.6%. Biopharmaceuticals is currently one of the fastest growing segments in the biopharmaceutical industry. During the course of our research, we identified 122 such companies that are developing either formulation technologies or novel systems for delivery of large molecule drugs. Further, several start-ups, with innovative technologies, have surfaced in the past decade and have contin...

Targeted cancer therapy is an upcoming area gaining strong foothold in the industry and has already become the focus of a number of pharmaceutical companies. Small molecule protein kinase inhibitors are a type of targeted therapy that involves small molecule drugs administered in the cancer patient for specifically targeting certain proteins, called kinases, involved in the growth of cancer cells. In fact, non-tyrosine kinase inhibitors have gradually gained attention in the last few years. Ther...

The service oriented and dynamic nature of the healthcare industry has led to the discovery of a plethora of treatment options for a wide range of ailments. Rare / orphan diseases, as the name suggests, are those diseases which are relatively infrequent in occurrence. The prevalence and adversity of these ailments has gained significant attention in the global healthcare industry. The enactment of the Orphan Drugs Act in the US and EU emerged as ground breaking and provided the necessary support...

The focus of drug developers is gradually moving towards immunotherapeutics, which make use of the body

Oral targeted therapeutics has attracted many drug developers due to the ease of administration it offers to patients (especially pediatric and geriatric patients). However, the high price of these drugs still remains a major constraint to the market growth. Further, as leukemia accounts for about 3% of all cancer cases per year, most of the companies are targeting other cancer indications offering a wider market prospective. Notably, there are specific opportunities which remain to be tapped in...

With nearly 300 million dry eye sufferers worldwide, dry eye represents one of the largest ophthalmic indications. The prevalence of dry eye syndrome primarily increases with age, and has an estimated incidence of 15% in persons over the age of 65 years. In fact, tn the US alone, the economic burden of dry eye totals USD 3.84 billion in direct annual health care costs. After including the indirect costs of lost productivity, the societal burden of dry eye rises to USD 55.4 billion annually in t...